Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 6/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280215 | 1.00 | GLO1 (0.73) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL28984590 | 0.94 | GLO1 (0.65) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL28984553 | 0.92 | GLO1 (0.63) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL11874436 | 0.91 | GLO1 (0.59) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL5000996 | 0.91 | GLO1 (0.59) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL11873695 | 0.90 | GLO1 (0.59) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL11867595 | 0.90 | GLO1 (0.59) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL11867575 | 0.90 | GLO1 (0.59) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL11873669 | 0.90 | GLO1 (0.59) | GLO1PTGS1GSTK1ACEFOLH1 | |
| SCHEMBL11874744 | 0.87 | GLO1 (0.56) | GLO1PTGS1GSTK1ACEFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | claimed |
| WO-2022074181-A1 | NANOCARRIER FORMULATIONS FOR INHALATION | EnhanX Biopharm Inc. (TW) | 2022-04-14 | — | — | WO | claimed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | claimed |
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | MIRECA MEDICINES GMBH (DE) | 2019-06-18 | — | — | US | claimed |
| EP-2398500-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2 BBB MEDICINES B V (NL) | 2019-03-13 | — | — | EP | claimed |
| EP-3395372-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2-BBB Medicines B.V. (NL) | 2018-10-31 | — | — | EP | claimed |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2018-03-29 | — | — | US | claimed |
| EP-3270889-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | Mireca Medicines GmbH (DE) | 2018-01-24 | — | — | EP | claimed |
| WO-2016146669-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2016-09-22 | — | — | WO | claimed |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2014-08-14 | — | — | US | claimed |
| EP-2398500-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB Holding B.V. (NL) | 2011-12-28 | — | — | EP | claimed |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2011-12-15 | — | — | US | claimed |
| WO-2010095940-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2010-08-26 | — | — | WO | claimed |
| US-7700560-B2 | Inactivators and bivalent inhibitors of glyoxalase I and methods of inhibiting tumor growth | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2010-04-20 | — | — | US | claimed |
| US-20070129311-A1 | Inactivators and bivalent inhibitors of glyoxalase i and methods inhibiting tumor growth | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2007-06-07 | — | — | US | claimed |
| JP-2006526632-A | — | — | 2006-11-24 | — | — | JP | claimed |
| EP-1628999-A4 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | UNIV MARYLAND (US) | 2006-08-23 | — | — | EP | claimed |
| US-20060148020-A1 | Inhibitors of gst a3-3 and gst a1-1 for the treatment of cancer | MANNERVIK, BENGT (SE) | 2006-07-06 | — | — | US | claimed |
| EP-1628999-A2 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | University of Maryland, Baltimore County (US) | 2006-03-01 | — | — | EP | claimed |
| WO-2005007079-A2 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2005-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | PDE6C, PDE2A, GMPS | GLO1 155/4885PTGS1 131/4885GSTK1 64/4885 |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | GLO1 93/4885PTGS1 292/4885GSTK1 13/4885 |
| US-20070129311-A1 | Inactivators and bivalent inhibitors of glyoxalase i and methods inhibiting tumor growth | GLS, GLO1, GLRX3 | GLO1 2/4885PTGS1 324/4885GSTK1 27/4885 |
| US-20060148020-A1 | Inhibitors of gst a3-3 and gst a1-1 for the treatment of cancer | GSTA1, GSTK1, GSTM1 | GLO1 62/4885PTGS1 35/4885GSTK1 2/4885 |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | PDE6C, PDE2A, GMPS | GLO1 166/4885PTGS1 131/4885GSTK1 71/4885 |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | GLO1 93/4885PTGS1 292/4885GSTK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.